Business

Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and… Read more . . .

Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical… Read more . . .

Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler,… Read more . . .

Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university’s Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was… Read more . . .

Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors… Read more . . .

Teva Israel and Syqe Medical have announced that Teva will distribute Syqe’s cannabis inhaler in Israel, with Syqe responsible for manufacturing the inhaler and cartridges. No financial terms were disclosed. The Syqe device delivers 100… Read more . . .

On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck’s US patent 6,127,353 but finding that Teva’s mometasone nasal spray ANDA does not… Read more . . .

Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health… Read more . . .

According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which “All issues arising out of the license and collaboration agreement, the supply agreement,… Read more . . .